A new pancreatic cancer drug has shown significant promise in a trial, with reports indicating it nearly doubles survival rates for patients with the disease. The drug, referred to as daraxonrasib in some reports, has been described as a breakthrough in treating one of the deadliest forms of cancer. Some outlets have noted that the treatment can also improve quality of life for patients.